SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
CAMBRIDGE, Mass., Feb. 05, 2016 -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the fourth quarter and year ended December 31, 2015 before the U.S. financial markets open on Thursday, February 18, 2016.
Management will host a conference call on that date at 10:00 a.m. EST to discuss these results and provide an update on the company. To access the call, please dial (877) 224-9084 (domestic) or (720) 545-0022 (international) prior to the scheduled conference call time and provide the access code 46315104. A live webcast of the call will be available on the "Investors" section of the company's website, www.momentapharma.com. Please go to the site at least 15 minutes prior to the call in order to register, download, and install any necessary software. An archived version of the webcast will be posted on the Momenta website approximately two hours after the call.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Contact: Sarah Carmody Momenta Pharmaceuticals 1-617-395-5189 [email protected]
